BIG News. New Name. New Look. Same Mission: to forge a new era of psychiatry by  applying scientific rigor to psychedelics – developing accessible treatments that unlock healing at scale. Meet Definium Therapeutics. Guided by precision, fueled by our combined decades of

Did you know? Generalized anxiety disorder (GAD) affects ~26M adults in the U.S. New peer-reviewed research published in the Journal of Affective Disorders examines the clinical and economic burden of GAD—including the impact of being undiagnosed. Findings highlight lower

We’re pleased to announce the appointment of Roger Adsett to our Board of Directors. A seasoned biopharmaceutical leader, Roger brings deep experience building high-performing commercial organizations and guiding therapies from launch to meaningful market impact. 👉 Read the

Widely studied, then sidelined for decades, pharmaceutical LSD is now being re-examined for its potential to help patients living with mental health disorders. Learn more: https://t.co/P9UQtDnzu2 #DefiniumTherapeutics #Definium #BrainHealth #ReroutingMinds #Biotech

There is immense clinical potential in psychedelics. Learn more about Definium’s commitment to Rerouting Minds: https://t.co/P9UQtDnzu2 #DefiniumTherapeutics #Definium #BrainHealth #MentalHealthInnovation #Biotech #FutureOfPsychiatry #ReroutingMinds

On the heels of our exciting launch as Definium Therapeutics, we’re excited to have been at #ACNP2026! We presented four posters brimming with insights, such as treatment patterns for newly diagnosed GAD, gathered from real-world evidence: https://t.co/J8Ij9CFwIE

Definium Therapeutics lit up the Nasdaq tower today as we officially begin trading under our new name and ticker, $DFTX. This moment marks the next leap forward for our company and further showcases who we are, what we do, how we do it, and the precision and scientific rigor

Join Definium Therapeutics CEO Rob Barrow at the 44th Annual J.P. Morgan Healthcare Conference. 📅 Wednesday, January 14 ⏰ 2:15 PM PT / 5:15 PM ET Rob will discuss our exciting year ahead, anchored by our four phase 3 pivotal trials of DT120 ODT, redefining what treatment

What defines our next chapter? Breakthrough Science. Bold Innovation. Transformational. Boundless. Precision. Rigor. More to come — stay tuned.

We believe progress shouldn’t inch ahead; it should leap forward. A bold new era is coming.

MindMed will participate in the 44th Annual J.P. Morgan Healthcare Conference. Our CEO, Rob Barrow, will present on January 14, 2026, at 2:15 p.m. PT, highlighting our progress and outlook as we head into a defining year with three anticipated Phase 3 topline readouts, two in

We will participate in two key investor conferences in December. Our leadership team will discuss company progress, recent developments, and our long-term focus on improving brain health. 8th Annual Evercore Healthcare Conference Format: Fireside Chat December 2, 2025 |

We were proud to sponsor this year’s Women in Government Leadership & Innovation Summit—an inspiring gathering of state legislators and policy leaders working to strengthen communities nationwide. Over two days in San Diego, attendees explored timely issues shaping public health

Our Senior Director of Toxicology, Julie Tripp, DABT, will share insights from MindMed’s preclinical research program, highlighting the rigor and innovation that drive our commitment to developing safe and effective approaches for brain health. We’re honored to join global

We published our Q3 2025 financial results and business updates today. A replay of this afternoon’s conference call is now available. Read the full press release here: https://t.co/pCUsS4ZlsK

MindMed has announced the closing of a $259 million equity financing, underscoring strong support from leading healthcare investors and confidence in the company’s long-term strategy and mission. This financing strengthens MindMed’s position to advance our work in brain health

We will report our Q3 2025 financial results and business updates during a live webcast at 4:30 p.m. EST on November 6, 2025. See press release here for details and to register: https://t.co/gIDg17zn6v